Integrated Diagnostics Holdings Plc

Company Announcement

3 November 2016

IDH Appoints Vice President Finance and Strategy

(Jersey) Integrated Diagnostics Holdings ("IDH" or "the Group"), IDHC on the London Stock Exchange, Egypt's largest fully integrated private-sector provider of medical diagnostics services, announced today the appointment of Omar Bedewy as Vice President Finance and Strategy.

Mr. Bedewy has more than 16 years of financial services experience acquired in the Middle East North Africa (MENA) region. Having worked in investment banking, private equity and investment consultancy, he brings to IDH a diverse background in transactions, including M&A advisory, financial restructuring and capital raising services for both buy- and sell-side clients.

Mr. Bedewy began his career on PricewaterhouseCooper's corporate finance team, where he was broadly exposed to due diligence and financial advisory transactions. He later became part of the newly-established Citadel Capital subsidiary ASEC as Investment and M&A Manager, assisting the group in acquisitions across the MENA region. During this time, his team spearheaded successful investments and transactions in Sudan, Algeria, Libya, Iraq and Egypt. Prior to joining IDH, Mr. Bedewy was financial advisor to Easy Group, where he led a restructuring plan that included the raising of new debt facilities to finance expansion plans. He holds a BS in Economics from Cairo University and is both a Chartered Alternative Investment Analyst (CAIA) and Financial Risk Manager (FRM).

Commenting on Mr. Bedewy's appointment, Dr. Hend El Sherbini, Group Chief Executive Officer at IDH, said, "We are pleased to have a professional with Omar's background and experience join our company. He brings key strengths to our financial and management teams as we focus on expanding our footprint in Egypt and across the MENA region."

-End-

About Integrated Diagnostics Holdings (IDH)

IDH is the largest fully integrated private-sector medical diagnostics services provider in Egypt, comprehensively offering pathology and molecular diagnostics, genetics testing and basic radiology. IDH's core brands include Al Borg and Al Mokhtabar in Egypt, as well as Biolab (Jordan), Ultralab and Al Mokhtabar Sudan (both in Sudan) and the Medical Genetics Center, which operates in Egypt. IDH is listed on the London Stock Exchange (ticker: IDHC) and was founded in 2012 by the merger of Al Borg and Al Mokhtabar, the most established diagnostics services brands in Egypt.

IDH's forward looking strategy rests on leveraging its established business model to achieve five key strategic goals, namely: (1) continue to expand customer reach; (2) increase the number of tests per patient; (3) use the Mega Lab's enlarged capacity to provide services to third party labs and hospitals; (4) introduce new medical services by leveraging the Group's network and reputable brand position; and (5) expand into new geographic markets through selective, value accretive acquisitions. Learn more at idhcorp.com.

Shareholder Information

LSE: IDHC.L

Bloomberg: IDHC:LN

Listed: May 2015

Shares Outstanding: 150 million

Contact

Mr. Sherif El-Ghamrawi

Investor Relations Director

T: +20 (0)2 3345 5530 | M: +20 (0)10 0447 8699 | sherif.elghamrawi@idhcorp.com